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A R T I C L E   I N F O S U M M A R Y 
Concerns regarding the safety of cumulative exposure to parabens have been raised 
as a consequence of their estrogenic and endocrine effects. These antibacterial agents 
are commonly used in food, pharmaceutical and cosmetic products. Preliminary 
data from animal models has indicated potential links between paraben exposure 
and various conditions ranging from skin disorders to autism. Oral consumption of 
parabens is not a cause for concern because they are readily metabolised by the liver 
and excreted rapidly by the kidney. The presence of parabens in adipose tissue is 
thought to be due to dermal absorption of parabens where they are incompletely 
metabolised. Various studies have been performed on paraben absorption; however 
transdermal permeation of parabens from an emulsion has not been studied to date. 
In this preliminary study dermal permeation and metabolism across human skin 
were evaluated for methyl paraben (MP) and butyl paraben (BP) from an emulsion, 
using Franz Diffusion cell system with analysis by q-ToF (quadrupole time of flight) 
mass spectrometry. MP was observed to have lower permeation and lower extent of 
metabolism than BP. 
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INTRODUCTION 
Parabens have been used as preservatives in food, 
pharmaceutical and cosmetic products for over 50 
years (Soni 2005). Humans are exposed to parabens by 
dermal contact and ingestion. When ingested, 
parabens are metabolised by the liver, thus higher 
tissue concentrations of native paraben occur when 
dermally absorbed. Preliminary animal studies 
proposed a link between cases of autism and paraben 
exposure (Ali and Elgoly, 2013; Hegazy et al, 2015) 
implying that use of paraben-containing formulations 
on the skin could be a potential ‘risk’ factor. The aim 
of our study was to examine the extent of diffusion 
and metabolism of MP and BP via human skin. 
MATERIALS AND METHODS 
20g of oil-in-water creams were prepared as described 
in Dodou et al. (2015). Formulations containing 1% 
w/w paraben (n=3) were prepared by adding the 
paraben (MP or BP) to the oily phase. Water was then 
added slowly to the oil phase at the same temperature. 
A paraben-free cream was used as control. 
In-vitro skin permeation studies: Human abdominal 
skin from one donor (thickness=500µm) was mounted 
in 8 glass Franz cells (absorption surface area = 
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0.79 cm2). Skin samples were placed between the 
donor and receptor chambers, with the dermis in 
contact with the receptor medium. The receptor 
chamber was filled with ~1.5ml of PBS, stirred 
continuously with a magnetic stirrer while incubated 
at 37±0.5°C. The paraben-free cream was applied to 
the donor chamber of cell 1 and medicated cream to 
cells 3-9 (n=6); 15mg of formulation was applied to the 
donor chamber of each cell, yielding a specific dose of 
75µg/cm2 of paraben. Receptor fluids were removed 
at different time intervals (1, 2, 4, 6, 24 h) and cells 
filled with ~1.5ml of fresh preheated PBS. Analysis of 
paraben and metabolite content in the receptor fluid 
samples, skin swabs and skin digests was performed 
via chromatographic separation using a 4.6mmx50 
mm, 1.8-mm particle size Agilent XDB-C18 column 
(Agilent Technologies, Santa Clara, CA). The 
separation was performed isocratically with 50% A 
(10mMol Ammonium Acetate/Water) and 50% B 
(10mMol Ammonium Acetate/Methanol), at a flow 
rate of 0.6 ml/min, a run time of 8 min, autosampler 
temperature at 5℃ and injection volume of 40ul. All 
samples were analyzed on a 1200 Series HPLC  system 
coupled to a 6530 Quadrupole Time of Flight (q-ToF) 
accurate mass spectrometer system with Jet Stream   
electrospray   source   (Agilent Technologies) operated 
in the negative-ion mode. ESI capillary voltage was set 
at 3000V and fragmentor at 100V. 
RESULTS AND DISCUSSION 
BP showed higher % metabolism to para-hydroxy 
benzoic acid compared to MP (Figure 1). The higher 
lag time of BP (1.9 h) compared to MP (0.6 h) (Table 1) 
was indicative of the quicker diffusion of MP through 
the skin. 
  
Fig. 1. % Metabolism of MP and BP. 
 
Table 1. Permeation parameters of MP and PB in human skin. 
 Methyl paraben 
 ±SD 
Butyl paraben 
±SD 
Peak flux 
(µg/cm2/h) 
0.017 ± 0.01 0.21 ± 0.6 
Lag time (h) 0.6 ± 0.4 1.9 ± 0.2 
% Recovered dose 8 ± 0.9 72.2 ± 8.7 
CONCLUSIONS 
Considering the difference of the extent of skin 
metabolism between the tested parabens, a systematic 
study of all parabens would be useful to allow their 
ranking in terms of potential risk. 
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